Related Experiment Video
Updated: Mar 27, 2026
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
New developments in giant cell arteritis
Larry Frohman1, Aaron B C Wong2, Kaliopy Matheos2
1Department of Ophthalmology, Rutgers-New Jersey Medical School, New Jersey, USA; Department of Neurosciences, Rutgers-New Jersey Medical School, New Jersey, USA.
Insights
Giant cell arteritis (GCA) diagnosis and treatment are evolving. Temporal artery biopsy remains key, but new imaging and therapies like IL-6 inhibitors show promise for this large vessel vasculitis.
Area of Science:
- Rheumatology
- Immunology
- Vascular Medicine
Background:
- Giant cell arteritis (GCA) is a serious medium-to-large vessel vasculitis.
- Recent advancements challenge traditional diagnostic guidelines and understanding of GCA.
- The American College of Rheumatology criteria for GCA diagnosis face scrutiny.
Purpose of the Study:
- To review current understanding of GCA pathogenesis, diagnosis, and treatment.
- To highlight evolving diagnostic approaches and therapeutic strategies for GCA.
- To discuss the relationship between GCA, Takayasu arteritis, and polymyalgia rheumatica.
Main Methods:
- Review of recent literature on GCA pathogenesis, diagnosis, and treatment.
- Analysis of the utility of temporal artery biopsy in current clinical practice.
- Evaluation of emerging diagnostic modalities like positron emission tomography (PET).
Main Results:
- Erythrocyte sedimentation rate (ESR) can be affected by medications (statins, NSAIDs) and hematocrit levels.
- Temporal artery biopsy remains the gold standard for GCA diagnosis, even with shorter lengths or delayed timing post-steroids.
- PET imaging reveals widespread vascular inflammation in GCA, suggesting a broader disease spectrum.
Conclusions:
- GCA, Takayasu arteritis, and polymyalgia rheumatica may represent a disease spectrum rather than distinct entities.
- Interleukin-6 (IL-6) inhibitors show significant promise as a novel therapeutic option for GCA.
- Combined therapies involving corticosteroids and immunosuppressants are crucial for managing GCA.
Abstract:
Giant cell arteritis (GCA) is a medium-to-large vessel vasculitis with potentially sight- and life- threatening complications. Our understanding of the pathogenesis, diagnosis, and treatment of GCA has advanced rapidly in recent times. The validity of using the American College of Rheumatology guidelines for diagnosis of GCA in a clinical setting has been robustly challenged. Erythrocyte sedimentation rate, an important marker of inflammation, is lowered by the use of statins and nonsteroidal anti-inflammatory drugs. Conversely, it may be falsely elevated with a low hematocrit. Despite the emergence of new diagnostic modalities, temporal artery biopsy remains the gold standard. Evidence suggests that shorter biopsy lengths and biopsies done weeks to months after initiation of steroid therapy are still useful. New imaging techniques such as positron emission tomography have shown that vascular inflammation in GCA is more widespread than originally thought. GCA, Takayasu arteritis, and polymyalgia rheumatica are no longer thought to exist as distinct entities and are more likely parts of a spectrum of disease. A range of immunosuppressive drugs have been used in conjunction with corticosteroids to treat GCA. In particular, interleukin-6 inhibitors are showing promise as a therapy.
